Stock IMMP IMMUTEP ADR
Add to a list
To use this feature you must be a member
Log inSign up

Financials Immutep ADR Nasdaq

Equities

IMMP

US45257L1089

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 21/05/2024 am IST 		5-day change 1st Jan Change
3.1 USD +4.73% Intraday chart for Immutep ADR +5.80% +29.17%
17/05 Capital One Initiates Immutep at Overweight Rating With $10 Price Target MT
15/05 Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data MT

Valuation

Fiscal Period: Juni 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 84.71 75.58 411.5 247.7 374 558.8 - -
Enterprise Value (EV) 1 75.79 58.31 350.9 169.2 251.4 483.6 497.1 513.4
P/E ratio -4.39 x -4.61 x -10.9 x -7.65 x -7.05 x -12.3 x -13.1 x 34.7 x
Yield - - - - - - - -
Capitalization / Revenue 11.3 x 4.58 x - 36.7 x 71.9 x 157 x 37.6 x 5.01 x
EV / Revenue 10.1 x 3.53 x - 25 x 48.3 x 136 x 33.5 x 4.61 x
EV / EBITDA -4.14 x - -20 x -5.63 x -6.65 x -10.6 x -11.9 x 12.7 x
EV / FCF -4.94 x -5.37 x -19.9 x -5.59 x -7.09 x -10.1 x -8.89 x 9.55 x
FCF Yield -20.2% -18.6% -5.03% -17.9% -14.1% -9.89% -11.2% 10.5%
Price to Book - - - 2.62 x 2.74 x 5.6 x 9.93 x 4.56 x
Nbr of stocks (in thousands) 3,38,860 4,87,631 7,48,153 8,54,123 11,87,306 11,88,835 - -
Reference price 2 0.2500 0.1550 0.5500 0.2900 0.3150 0.4700 0.4700 0.4700
Announcement Date 20/08/19 25/08/20 30/08/21 31/08/22 29/08/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Juni 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 7.489 16.5 - 6.758 5.2 3.551 14.85 111.5
EBITDA 1 -18.32 - -17.59 -30.05 -37.81 -45.83 -41.64 40.57
EBIT 1 -20.2 -12.31 -19.66 -32.12 -39.88 -47.14 -44.99 12.95
Operating Margin -269.66% -74.61% - -475.26% -766.83% -1,327.44% -302.89% 11.61%
Earnings before Tax (EBT) 1 -18.34 -13.47 -29.9 -32.21 -39.9 -45.42 -44.81 20.93
Net income 1 -18.34 -13.47 -29.9 -32.21 -39.9 -45.01 -44.23 0.64
Net margin -244.93% -81.63% - -476.63% -767.22% -1,267.7% -297.82% 0.57%
EPS 2 -0.0570 -0.0336 -0.0503 -0.0379 -0.0447 -0.0383 -0.0359 0.0135
Free Cash Flow 1 -15.33 -10.86 -17.66 -30.25 -35.44 -47.84 -55.9 53.77
FCF margin -204.66% -65.81% - -447.65% -681.49% -1,347.35% -376.38% 48.23%
FCF Conversion (EBITDA) - - - - - - - 132.54%
FCF Conversion (Net income) - - - - - - - 8,401.72%
Dividend per Share 2 - - - - - - - -
Announcement Date 20/08/19 25/08/20 30/08/21 31/08/22 29/08/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 - - - - 2.08 3.906 - 2.617 4.11 1.2
EBITDA 1 - - -9.341 -8.245 -14.95 -15.68 - - - -23.55
EBIT 1 -5.373 -6.938 -10.39 -9.262 -16.84 -15.86 -20.61 -19.27 -21.22 -25.25
Operating Margin - - - - -809.62% -405.89% - -736.14% -516.19% -2,104.17%
Earnings before Tax (EBT) 1 -5.95 -7.518 -19.84 -10.06 -16.27 -15.94 -20.62 -19.27 -21.23 -24.27
Net income 1 -5.95 -7.518 -19.84 -10.06 -16.27 -15.94 -20.62 -19.27 -21.23 -24.35
Net margin - - - - -782.21% -408.07% - -736.35% -516.45% -2,029.17%
EPS 2 - - -0.0383 -0.0120 -0.0200 -0.0185 -0.0236 - -0.0179 -0.0193
Dividend per Share - - - - - - - - - -
Announcement Date 20/02/20 25/08/20 23/02/21 30/08/21 24/02/23 31/08/22 24/02/23 29/08/23 27/02/24 -
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 8.93 17.3 60.6 78.5 123 75.1 61.7 45.4
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -15.3 -10.9 -17.7 -30.3 -35.4 -47.8 -55.9 53.8
ROE (net income / shareholders' equity) - - -56.1% -38.5% -34.6% -48.1% -104% -34.6%
ROA (Net income/ Total Assets) - - -46.5% -35% -32% -44.2% -127% -137%
Assets 1 - - 64.32 92.1 124.8 101.8 34.88 -0.4678
Book Value Per Share 2 - - - 0.1100 0.1100 0.0800 0.0500 0.1000
Cash Flow per Share 2 - - -0.0300 -0.0400 -0.0400 -0.0200 -0.1000 -
Capex 1 0.04 0.02 0.02 0.02 0.08 0.05 0.07 0.08
Capex / Sales 0.55% 0.12% - 0.34% 1.59% 1.32% 0.45% 0.07%
Announcement Date 20/08/19 25/08/20 30/08/21 31/08/22 29/08/23 - - -
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Immutep ADR

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.47 AUD
Average target price
0.978 AUD
Spread / Average Target
+108.09%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+41.79% 50.93B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.56% 42.12B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.05B
CELLTRION, INC. Stock Celltrion, Inc.
-7.20% 29.18B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.59% 26.02B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.51% 18.9B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+6.92% 13.21B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.91% 12.17B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.60% 12.16B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IMM Stock
  4. IMMP Stock
  5. Financials Immutep ADR
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW